Stock screenerAll disclosures →
EDGAR →
NERV
Conviction 47HealthcareScan · Mon, Aug 10, 2026NERV$4.63+8.43%
ResistanceSupportVol 14Vol MA14 215.52K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price4.63
Change+8.43%
Gap+1.17%
Rel volume7.17×
Avg volume206.15K
Avg $ vol898.69K
SMA 204.24
SMA 504.51
SMA 2005.03
Price vs 50+2.69%
Price vs 200-8.03%
MA stackmixed
50/200 cross—
Supertrenddown · 5.07
RSI (14)56
MACD hist0.06
MACD crossbull · 3d
Stoch %K / %D94 / 72
ADX (14)14
+DI / −DI19 / 14
RSI divergenceBullish
MACD divergence—
ATR %+7.94%
ADR %8.29%
52w high8.07
52w low1.76
From 52w high-42.63%
Above 52w low+163.07%
New 52w highNo
SqueezeOn · 7d
Bollinger width17.77%
%B1.01
Donchian pos93.98%
Donchian high4.68
Donchian low3.85
AVWAP (52w high)7.70
vs AVWAP high-39.84%
AVWAP (52w low)7.36
vs AVWAP low-37.07%
OBV trendUp
Chaikin MF (20)0.28
Today vs 20d7.17×
Avg vol (14d)215.52K
Avg vol (20d)206.15K
Avg $ vol (20d)898.69K
Market cap221.07M
RS 3m (vs SPY)-35.98%
RS 6m (vs SPY)-12.93%
RS line new highNo
Trend template4/8
Technical rank40.3
1 week+16.62%
1 month-1.91%
3 months-21.26%
6 months-3.54%
1 year+157.85%
YTD+18.11%
P/E-0.75
P/B-1.04
P/S—
P/FCF-16.34
EPS-34.67
Div yield—
ROE137.56%
ROA-308.58%
Debt/Eq-0.04
Current20.14
EV/EBITDA-13.64
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value205.81M
Revenue0
Net income17.47M
Gross profit—
Free cash flow-13.53M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out46.59M
Employees7
ListedTue, Jul 1, 2014
Free float33.24M
Float %75.8%
Short interest2.42M
Days to cover12.5d
Short volume61.9%
Squeeze score69 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank40.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance5.35
Support3.90
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in NERV
No recent disclosed trades by Congress in NERV. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NERV · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Laghrissi-Thode Fouzia Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
VAN HEEK G JAN Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
HASLER HANS PETER Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Kupfer David Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Luthringer Remy CEO · Employee Stock Option (right to buy) · 2026-06-03 | Grant | 1.69M | $0 | 2026-06-03 | 2026-06-05 |
Kaul Inderjit Director · Stock Option (right to buy) · 2026-06-03 | Grant | 50K | $0 | 2026-06-03 | 2026-06-05 |
Ahlholm Frederick W SVP, CFO and Secretary · Employee Stock Option (right to buy) · 2026-06-03 | Grant | 680K | $0 | 2026-06-03 | 2026-06-05 |
O'Connor James Joseph Chief Business Officer and GC · Employee Stock Option (right to buy) · 2026-04-21 | Grant | 350.8K | $0 | 2026-04-21 | 2026-04-22 |
SEC filings
EDGAR filings in NERV · 4 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.